Formulary - Drug-related clinical news & analysis for hospital & managed-care P&T members

ADVERTISEMENT
Previous StoryPlay / PauseNext Story
Focus On . . .
Rifaximin: A nonabsorbable, broad-spectrum antibiotic for reduction in the risk for recurrence of overt hepatic encephalopathy
A recent landmark phase 3 trial in patients in remission from recurrent hepatic encephalopathy demonstrated that rifaximin at a dose of 550 mg twice daily is significantly more effective than placebo in maintaining remission and reducing the risk of hospitalization. Rifaximin's approval by FDA in March 2010, offers clinicians the first pharmacologic treatment for hepatic encephalopathy in more than 30 years.
Clinical News
New treatment launched for migraines in U.S.
A neurology-focused specialty pharmaceutical company has launched diclofenac potassium for oral solution (Cambia, Nautilus Neurosciences Inc.) for the acute treatment of migraine with or without aura in the United States. FDA approved the prescription medication in June 2009.
Costs thwart continued care for many cancer patients
Many cancer survivors delay or forgo medical care due to cost, and cancer survivors aged <65 are more likely to put off or forgo care than those without a history of cancer, according to research published online June 14 in Cancer, reported HealthDay News.
Year of weekly exenatide beneficial in type 2 diabetes
In patients with type 2 diabetes, a once-weekly formulation of exenatide (Byetta, Amylin Pharmaceuticals) is associated with sustained improvements in glycemic control and body weight over 52 weeks, and patients who switch from a twice-daily to a once-weekly regimen have further improvements in hemoglobin A1C and fasting plasma glucose, according to research published in the June issue of Diabetes Care, as reported in HealthDay News.

ADVERTISEMENT



Stay connected to Formulary
Receive web-exclusive articles, clinical news, and conference updates!
Newsletter signup
SUGGESTION BOX
Click here to leave a comment in our suggestion box.

Modern Medicine logoFormulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.
Register now (it's free and quick) or Find out more.

Keep visiting FormularyJournal.com for fresh content, news, opinions, editor's blogs and more.

MEDWATCH DRUG SAFETY UPDATES
Evamist (estradiol transdermal spray): Drug Safety Communication - Unintended Exposure of Children and Pets to Topical Estrogen
Cubicin (daptomycin): Drug Safety Communication - Risk of Eosinophilic Pneumonia
Joyful Slim Herb Supplement : Recall-Undeclared Drug Ingredient
Cook brand Ciaglia Blue Rhino/Ciaglia Blue Dolphin Percutaneous Tracheostomy Introducer Sets and Trays
CONSTELLATION Vision System: Recall

Last updated on Thu Jul 29 14:00:00 EDT 2010

FORMULARY SURVEY OF THE MONTH
A recent trial, published in the New England Journal of Medicine, concluded that the statin drug Crestor (rosuvastatin) lowered the combined risks of heart attack, stroke, other heart events or heart-related death by 47% in healthy patients with no history of heart problems or high cholesterol but high levels of C-reactive protein (CRP), a marker for inflammation.
Do you believe that healthy people should take statins?
Yes
No
Yes
39%
No
61%

ADVERTISEMENT

Modern Medicine is a new online resource designed to meet the evolving needs of physicians. It brings together elements from Advanstar's trusted healthcare journals along with powerful tools, resources, decision support and advisory functions.

Click here